Polyganics announces divestment of its ENT activities

/in /by

Groningen, the Netherlands, 7 November 2014 – Polyganics today announces it has signed an agreement to sell its activities in the field of Ear, Nose and Throat (ENT) surgery to Stryker. The ENT activities comprise a portfolio of sinunasal and otological dressings, including the marketed products NASOPORE®, HEMOPORE®, OTOPORE® and NASOPORE-FD®. As part of the agreement, Polyganics will continue to manufacture these products in the coming years.

“This is a very important step in our strategy to focus on the successful medical device development based on our proprietary synthetic polymer platforms,” says Rudy Mareel, CEO of Polyganics. “We strongly believe Stryker is the best partner to maximize the commercial potential of our ENT portfolio.”

About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The Company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

The existing portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. Surgical applications include peripheral nerve repair, neuro-, general, as well as ear, nose & throat surgery.

Polyganics is profitable, privately held, and based in Groningen, The Netherlands, a center of biomedical engineering excellence. The Company’s polymer platform technologies are protected by a broad portfolio of patents.

For more information, please visit www.polyganics.com

Polyganics obtains FDA 510k clearance to market HEMOPORE®

/in /by

Groningen, the Netherlands, 23 October 2014 – Today, Polyganics announces it has obtained FDA clearance for HEMOPORE®. HEMOPORE® offers two forms of post-op hemostatic control in one bioresorbable sinunasal dressing. The clearance comes after the CE regulatory approval of NASOPORE FD® in April 2014 and FDA 510k approval of NASOPORE FD® in October 2014.

“This a significant step in the extension of our successful NASOPORE® product family”, says Rudy Mareel, CEO of Polyganics. “We believe the unique characteristics of HEMOPORE® offer a valuable new treatment option to doctors.”

About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The Company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

The existing portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. Surgical applications include peripheral nerve repair, neuro-, general, as well as ear, nose & throat surgery.

Polyganics is profitable, privately held, and based in Groningen, The Netherlands, a center of biomedical engineering excellence. The Company’s polymer platform technologies are protected by a broad portfolio of patents.

For more information, please visit www.polyganics.com

Polyganics obtains FDA 510k clearance to market NASOPORE-FD®

/in /by

Groningen, the Netherlands, 7 August 2014 – Today, Polyganics announces it has obtained FDA clearance for NASOPORE-FD®, a sinunasal dressing with a rapid clearance time. The approval comes after the CE regulatory approval of NASOPORE-FD® in April 2014 and marks a next step in the commercialization Polyganics’ front-running bioresorbable nasal dressing portfolio marketed under the NASOPORE® brand.

“This is another important milestone in the extension of our successful NASOPORE® product family”, says Rudy Mareel, CEO of Polyganics. “We believe the unique characteristics of NASOPORE-FD® offer a valuable new option to doctors and are very excited that it now becomes available on the US market.”

About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The Company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

The existing portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. Surgical applications include peripheral nerve repair, neuro-, general, as well as ear, nose & throat surgery.

Polyganics is profitable, privately held, and based in Groningen, The Netherlands, a center of biomedical engineering excellence. The Company’s polymer platform technologies are protected by a broad portfolio of patents.

For more information, please visit www.polyganics.com

Polyganics obtains CE approval to market NASOPORE-FD®

/in /by

Groningen, the Netherlands, 17 April 2014 – Polyganics today announces the CE regulatory approval of NASOPORE- FD®, a sinunasal dressing with a rapid clearance time. NASOPORE-FD® is the latest addition to Polyganics’ front-running bioresorbable nasal dressing portfolio marketed under the NASOPORE® brand. After insertion, NASOPORE-FD® exerts moderate elastic compression on the surrounding tissue for 36-48 hours while absorbing surrounding fluids.

“This is an important milestone in the extension of our successful NASOPORE® product family”, says Rudy Mareel, CEO of Polyganics. “We believe the unique characteristics of NASOPORE-FD® offer a valuable new option to doctors.”

About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The Company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

The existing portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. Surgical applications include peripheral nerve repair, neuro-, general, as well as ear, nose & throat surgery.

Polyganics is profitable, privately held, and based in Groningen, The Netherlands, a center of biomedical engineering excellence. The Company’s polymer platform technologies are protected by a broad portfolio of patents.

For more information, please visit www.polyganics.com